Background. An infectious disease (ID) consultation (consult) is often obtained to treat patients with cryptococcosis due to the complex nature of the disease, but has never been demonstrated to impact outcomes.
Cryptococcus is one of the most common opportunistic fungal infections in humans. In the United States, cryptococcal disease is more common in patients without human immunodeficiency virus (HIV) infection [1, 2] . Several studies have shown a predisposition toward lower mortality in cryptococcal patients with HIV [1] [2] [3] , and worse outcomes in cryptococcal nonsolid organ transplant (SOT) patients who are HIV-uninfected [1, 2] . Treatment consistent with Infectious Diseases Society of America (IDSA) guidelines has been associated with improved outcomes in cryptococcal patients, both in selection of induction treatment [4] and management of opening pressure [5] . An important determinant of outcomes in patients with cryptococcosis is the presence of disseminated disease, defined as cryptococcemia (positive blood cultures) and/or meningitis [6] . In addition, the recommendation for treatment of severe pulmonary disease is similar to disseminated disease [6] . Early and aggressive therapy for disseminated and moderate to severe pulmonary cryptococcosis included amphotericin B (AmB) plus flucytosine (5-FC) in several studies [4, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Patients who have mild to moderate pulmonary infection, such as solitary nodule or pneumonia with mild symptoms, can be treated with fluconazole alone [6] .
Infectious disease (ID) consultation (hereafter, "consult") has been associated with lower mortality in patients with Staphylococcus aureus bacteremia [16] [17] [18] and candidemia [19] . Given the complexity and rarity of cryptococcal infection, we were interested in evaluating whether ID consultation was associated with a difference in outcomes in patients with cryptococcal infection. We also evaluated whether management recommended by ID compared to other physicians was more likely to follow evidence-based guidelines [6] . cryptococcal antigen (CrAg) or culture positive for Cryptococcus species. Latex agglutination was used exclusively for all serum and central nervous system (CSF) CrAg tests. Histopathology, if available, was used to define the site of disease. A standardized data collection tool was used to collect data on demographics, survival, predisposing factors, presentation, laboratory values, treatment, and whether an ID consult was obtained.
Patients in whom the diagnosis of cryptococcosis was made posthumously or <24 hours before death were excluded from analysis, as an ID consult could not have been reasonably obtained. In addition, patients who lacked sufficient clinical data in the medical record, had infection with non-neoformans species of Cryptococcus, or had a false-positive CrAg result (titer <1:8 that did not confirm on repeat test, and patient improved without treatment) were excluded from analysis. Because all HIV-infected patients in our hospital received an ID consult, and their outcomes, presentation and management were significantly different, they were excluded from the analysis. The remaining patients were classified into 2 groups, those who received an ID consult and those that did not.
Sites of infection and associated predisposing factors were defined as previously described [2] . The Elixhauser comorbidity classification was used to control for underlying health conditions, as it has been shown to be a good predictor of death in acute illness [20] .
Indications for a lumbar puncture (LP) and recommended treatment with AmB and 5-FC were defined based on the IDSA cryptococcal guidelines and recent review [6, 21] . LP was deemed appropriate if the patient had any of the following: (1) evidence of disseminated disease such as skin lesions, cryptococcemia, or Cryptococcus isolated from a normally sterile source; (2) positive serum CrAg with titer of ≥1:8; (3) symptoms indicative of central nervous system (CNS) disease (ie, headache, stiff neck, altered mental status, visual changes, or cranial nerve palsy); or (4) evidence of significant immunocompromise, specifically SOT, bone marrow transplant, hematologic malignancy, recent receipt of cytotoxic chemotherapy, end-stage liver disease, and receipt of immuncompromising medications.
Induction therapy with AmB and 5-FC was deemed appropriate in the presence of any of the following: (1) severe immunocompromise, defined as the same immunocompromising conditions indicating an LP; (2) severe pulmonary disease, defined as need for supplement oxygenation; (3) disseminated disease, as defined by CNS disease, cryptococcemia, or other extrapulmonary sites of infection; or (4) a high cryptococcal burden, defined by a serum CrAg titer of ≥1:512 [6] .
Dates of death were extracted from the hospital consortium's Medical Informatics database and supplemented with information from the Social Security Death Index (SSDI). Patients diagnosed with cryptococcal infection <90 days prior to the last available date in the SSDI (28 February 2014) who were not observed in our institution after the 90-day postdiagnosis period were censored at the date of last visit.
Attributable mortality was defined as the presence of 1 or more of the following: (1) an autopsy where the pathologist concluded the cause of death to be cryptococcus; (2) documented ongoing cryptococcal CNS disease and evidence of herniation; (3) multiorgan failure in the setting of ongoing cryptococcal infection within 14 days after diagnosis, and without evidence of another infection; (4) respiratory failure in the setting of cryptococcal pneumonia.
Statistical Analysis
Statistical analysis was performed using SPSS software version 23 (IBM, Armonk, New York). Fisher exact and Student t test or Mann-Whitney U test were used for descriptive statistics. A Cox proportional hazards model was used to evaluate the association of predisposing factors, comorbidities, location of disease, and antigen levels on all-cause and attributable mortality. Censoring was performed at 90 days, as mortality beyond 90 days was deemed less likely to be related to cryptococcal infection. For the initial multivariable Cox model, all variables with P < .2 were considered for entry in the model. The proportional hazards assumption for the multivariable model was assessed visually. Where this assumption was violated, we used a heavy-side step function to model the time interaction [22] . The final model was built with the significant variables in a parsimonious manner, and the c-statistic was computed. All statistical tests were 2-tailed and significance was set at α = .05.
RESULTS

Cohort
Two hundred fifty-eight patients met the initial inclusion criteria; 91 patients were excluded because they were HIV infected. An additional 20 patients were excluded because they lacked sufficient clinical data in the medical record (n = 5); had false-positive antigen tests (n = 3), died within 24 hours of diagnosis or were diagnosed postmortem (n = 5); or were infected by a non-neoformans species of Cryptococcus (n = 7). This included 2 cases of C. laurentii, and 1 case each of C. luteolus, C. albidus, C. uniguttulatus, C. humicolus, and 1 unidentifiable non-neoformans Cryptococcus species.
One hundred (68%) patients with an ID consult and 47 (32%) patients without an ID consult were included in subsequent analyses. Patients with an ID consult had a similar age as those who did not receive an ID consult (59.1 vs 59.6 years, respectively; P = .87). Most patients were male, and sex, race, and time to diagnosis were similar in the 2 groups ( Table 1 ). The distributions of predisposing factors were comparable in the ID and no consult groups, in all categories other than SOT, which was more common in the non-ID consult group (Table 1) .
Patients receiving ID consult appeared to have more-severe forms of cryptococcosis. Patients with an ID consult were significantly less likely to have pulmonary disease (27% vs 64%), but more likely to have cryptococcal meningitis (57% vs 11%). The presence of cryptococcemia and infection at other sites were similar between the 2 groups. The ID consult patients were more likely to have a positive CrAg in both serum and CNS, and also had higher antigen titers than patients in the non-ID consult group (Table 1) , consistent with a higher burden of disease.
Management
Patients receiving ID consult were significantly more likely to have appropriate performance of an initial diagnostic LP (86% vs 32%), but were there was no difference between the 2 groups in inappropriate performance of an LP (25% vs 30%) ( Table 2) .
ID consult patients were also significantly more likely to be started on appropriate AmB therapy (87% vs 24%). The duration of AmB therapy was significantly longer in the ID consult than non-ID consult group (14 vs 11 days). ID consult patients were also more significantly likely to receive 5-FC when indicated (57% vs 16%) and for a longer duration than the comparison group (7.5 days vs 1 day). No patient in either group received AmB or 5-FC if they could have been treated with fluconazole.
The ID consult group had more aggressive management of intracranial pressure (ICP), through the use of repeat LPs and (Table 3 ). The variables from the Elixhauser comorbidity index are reported in Supplementary Table 1 .
The association between age and mortality did not follow a linear relationship and was included in the multivariable model as a dichotomous variable. CSF CrAg levels were not significantly associated with mortality in univariate analysis, but serum levels were significantly associated with mortality, although the linearity of this association could not be assessed due to wide confidence intervals. A category of "disseminated disease, " defined as patients who had any disease other than localized pneumonia, was associated with significantly increased risk of mortality (Table 3 ).
In the final multivariable model, 5 factors were significantly associated with 90-day mortality (Table 4) . ID consult was associated with significantly lower mortality, with a HR of 0.24 (95% CI, .13-.45). Age >55 years, end-stage liver disease, positive cryptococcal antigen, and recent receipt of chemotherapy were also significantly associated with increased mortality in the multivariable model. When age was modeled in 5-year increments to assess for residual confounding, the HR for ID consult changed by <10% (HR, 0.23 [95% CI, .12-.45]). The C statistic of the final multivariable model was 0.785.
The difference in survival by ID consult status was most dramatic in the first 15 days, but persisted up until day 90 (Figure 1) . In a Cox model with an interaction of ID consult and time, ID consult was significantly associated with lower mortality through day 15 after diagnosis (HR, 0.15 [95% CI, .07-.34]) but was no longer associated with mortality after that (HR, 0.49 [95% CI, .17-1.38] from day 16 through day 90). This translates to a 6.5-fold protective association of an ID consult in the first 15 days, and nonsignificant 2.0-fold effect from days 16 to 90.
The cryptococcal-attributable mortality was 38 of 48 (79%) in the cohort; 20 of 27 (74%) in patients with an ID consult, and 18 of 21 (86%) in those without consult (P = .33). Patients who died of other causes included 7 (5 in the ID consult group) who died outside the hospital and the cause of death was not known, and 3 (1 in ID consult group) who had care withdrawn for their underlying condition, with a relatively well-controlled cryptococcal infection. Death occurred within 14 days of discharge in all patients with observed outpatient mortality.
The univariate and multivariable analyses were repeated with mortality attributable to cryptococcal infection, as defined above, as the dependent variable. In both univariate and multivariate analysis, the association of ID consult with cryptococcal morality was virtually the same as with all-cause mortality (HR, 0.45 [95% CI, .24-.84]; adjusted HR, 0.22 [95% CI, .12-.43]).
DISCUSSION
ID consult was associated with an adjusted HR of 0.24 for mortality, translating to a 4.2-fold high risk of mortality in patients who did not receive an ID consult. Despite the finding of a protective effect, patients with an ID consult had a higher fungal burden (as measured by higher CrAg levels in both CSF and serum), which has previously been associated with higher mortality rates [23, 24] .
The ID consult group was less likely to have had SOT (12% vs 26%), although SOT was marginally associated with lower mortality in our study, as well as others [1] , as has been the receipt of tacrolimus [25] , which the majority of the SOT patients in our population received.
Patients in the ID consult group were more likely to have meningitis (57% vs 11%), and less likely to have pulmonary disease (27% vs 64%). This, however, may reflect some ascertainment bias, as more patients with an ID consult received an appropriate LP. This was not as a result of an indiscriminate increase in LPs on the part of the consultants, as the proportion of LPs performed without an indication was similar. This finding raises the possibility that meningitis may have been missed in the no-consult group. This is important because the early and aggressive management of meningitis has also been associated with lower complication rates and improved outcomes in patients with cryptococcal meningitis [5, 26] . The lower use of LPs, leading to an increased likelihood of missed diagnoses of meningitis, could potentially explain the higher mortality in the group of patients who did not receive an ID consult. Similarly, to the finding of increased performance of LPs, the treatment for cryptococcal infection was more often adherent to evidence-based guidelines in patients with an ID consult compared to the no-consult group. Patients who had an indication for AmB (89% vs 24%) and 5-FC (71% vs 24%) received the antifungal therapy more frequently if they had an ID consult. In addition, when the appropriate induction therapy was given, the duration was also longer in the ID consult compared to the no-consult group. The ID consult group also received more interventions for their ICP management, including more repeat LPs and neurosurgical interventions. This could have contributed to decreased mortality, as successful management of ICP has been associated with improved outcomes [27] . However, opening pressure was not recorded in a consistent manner, so we cannot make any inferences regarding differences in opening pressure between groups.
Several other factors that were significantly associated with mortality in univariate analysis have been reported previously in the literature. Increased mortality has been observed in patients with cryptococcemia [1] , cirrhosis [2] , and advanced age [23] . Older age has previously been associated with increased 2-week mortality in cryptococcal meningitis [23] . Elevations of both serum cryptococcal antigen [12, 13, 28] , and another marker of cryptococcal burden, the quantitative cryptococcal culture [23] , have been associated with higher 2-week mortality. Due to our small sample size, we could not detect a dose response of cryptococcal burden, as assessed by CrAg levels, with mortality.
The variables associated with mortality in our final multivariable model included ID consult (protective), age >55 years, positive CrAg, end-stage liver disease, and receipt of chemotherapy within the past 90 days. Cryptococcemia was not included in the model as it was very highly correlated with a positive CrAg, and did not contribute significantly to the model. The receipt of chemotherapy was associated with 2.1-fold increased risk of mortality, although solid organ tumor was not, suggesting that it is not the metastatic cancer but rather the recent receipt of chemotherapy that appears to be associated with increased mortality in patients with cryptococcal infection.
We also found that the patients who received an ID consult underwent a diagnostic workup for meningitis more consistent with evidence based recommendations, and that they were more likely to receive AmB and 5-FC when indicated and to have more appropriate diagnostic LPs as well as more aggressive ICP management. It is likely that better diagnosis of the severity of cryptococcal infection with more appropriate antifungal management explains why an ID consult was beneficial in our cohort; however, the retrospective nature of this study does not allow us to prove causation. This study is limited by its retrospective nature, a single site, and the relatively small number of patients. However, despite the limited sample size, the receipt of an ID consult appears to be significantly associated with improved survival. Furthermore, we were unable to directly assess ICP in patients due to missing data. However, we were able to assess the number of LPs performed and use of neurosurgical interventions in the management of ICP. This is the first study that has examined the impact of ID consultation on the outcomes of patients with cryptococcosis. However, our findings parallel those from studies evaluating the effect of ID consultation in Staphylococcus aureus bacteremia. In that setting, ID consultation was associated with improved outcome, largely because of greater likelihood of diagnosing more complicated infections than initially realized, and greater likelihood of adherence to evidence-based guidelines for treatment.
In conclusion, in our cohort of 147 patients with cryptococcosis over 13 years, 32% of the patients had an opportunity for an ID consult but did not receive one, and this group of patients had significantly increased risk of death compared with patients who were seen by an ID physician. There was significantly lower all-cause and attributable mortality in the ID consult group, despite the fact that these patients had higher organism burden, and more evidence of disseminated cryptococcal disease. The lower mortality in the ID consult group may be due at least in part to increased adherence to management based on evidence-based recommendations, as patients seen by an ID physician were more likely to receive an appropriate LP and to be treated with AmB and 5-FC when indicated. Our results suggest that an ID consult is appropriate in all patients with cryptococcosis to improve outcomes and reduce mortality.
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